From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Simon Cheesman, MRPharmS, from University College London, London, UK, describes the key outcomes from the Phase III trial (NCT01696084) looking at CPX-351, a liposomal formulation of daunorubicin and cytarabine (DA), in a patient group aged between 60-75 years old. Compared with conventional DA chemotherapy, CPX-351 showed superior efficacy in terms of overall survival, with a comparable toxicity profile. Mr Cheeseman emphasizes the fact that dose administration is simpler and more convenient for both HCPs and patients.
Content on www.vjoncology.com and www.vjhemonc.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
